<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04806243</url>
  </required_header>
  <id_info>
    <org_study_id>NFEC-2021-010</org_study_id>
    <nct_id>NCT04806243</nct_id>
  </id_info>
  <brief_title>Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）</brief_title>
  <official_title>A Phase II, Second-line, Single-arm Clinical Trial of Carelizumab Combined With Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy and safety of carelizumab combined with regorafenib in&#xD;
      second-line treatment for patients with primary hepatocellular carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, there is little experience in the application of targeted drugs combined with&#xD;
      immunotherapy. Through this study, we hope to explore the optimal population for the use of&#xD;
      carelizumab combined with regorafenib in the second-line treatment of hepatocellular&#xD;
      carcinoma (HCC), as well as the efficacy and safety.&#xD;
&#xD;
      This research is a single-center trials phase II second-line, single arm, explore the&#xD;
      clinical outcome of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>os（overall survival）</measure>
    <time_frame>21 days</time_frame>
    <description>overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS（progression-free survival）</measure>
    <time_frame>21 days</time_frame>
    <description>progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTP（Time-To-Progression）</measure>
    <time_frame>21 days</time_frame>
    <description>Time-To-Progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR（Overall Response Rate）</measure>
    <time_frame>21 days</time_frame>
    <description>Overall Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR（disease control rate）</measure>
    <time_frame>21 days</time_frame>
    <description>disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR</measure>
    <time_frame>21 days</time_frame>
    <description>Duration of Response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Carelizumab Combined With Regorafenib arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib Pill&amp;Camrelizumab</intervention_name>
    <description>Regorafenib，80 mg，QD，Q3w Camrelizumab，200 mg，IV，Q3w</description>
    <arm_group_label>Carelizumab Combined With Regorafenib arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Not convenient to disclose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not convenient to disclose&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>NanFang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Li, Master</last_name>
      <phone>020-62787430</phone>
      <email>nfdoctorlee@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

